	US 12,268,682 B2
	Anticancer drug FL118 formulation for treatment of human cancer
Fengzhi Li, Buffalo, NY (US); Xiang Ling, Buffalo, NY (US); and Jianqun Liao, Buffalo, NY (US)
Assigned to Canget Bio Tekpharma, LLC, Buffalo, NY (US)
Appl. No. 17/629,537
Filed by CANGET BIOTEKPHARMA, LLC, Buffalo, NY (US)
PCT Filed Jul. 22, 2020, PCT No. PCT/US2020/043153 § 371(c)(1), (2) Date Jan. 24, 2022, PCT Pub. No. WO2021/016401, PCT Pub. Date Jan. 28, 2021.
Claims priority of provisional application 62/876,835, filed on Jul. 22, 2019.
Prior Publication US 2022/0249464 A1, Aug. 11, 2022
Int. Cl. A61K 31/4745 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); A61K 47/40 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01)

CPC A61K 31/4745 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2018 (2013.01); A61K 9/4858 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61K 40/4215 (2025.01); A61K 40/4222 (2025.01); A61K 45/06 (2013.01); A61K 47/40 (2013.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01)]

15 Claims

1. A formulation comprising:

an FL118 compound,

at least one cyclodextrin (CD), and,

an organic solvent or excipient,

wherein the organic solvent is methanol, ethanol, formic acid, a salt formate, acetic acid, a salt acetate, glyoxal, ethylene glycol, propylene glycol (PG), formamide, (N,N,N′,N′)-tetramethyl-ethylenediamine, ethanolamide, or 2-mercaptoethanol,

wherein the FL118 compound forms a complex with the at least one CD resulting in an CD-FL118 complex,

wherein the CD-FL118 complex has a fixed ratio of FL118:CD (w/w), and

wherein the CD-FL118 complex is within the range of 5-25% of the formulation.